In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Endotis Pharma closes its Series B round

Executive Summary

Endotis Pharma has raised €25mm ($36.2mm) through its Series B venture round. Wellcome Trust led the financing and was joined by Endeavour Vision, NIF SMBC Ventures, and returning backer Sofinnova Partners. The company will use the funds to continue developing compounds it in-licensed from Organon for arterial thrombosis and drug candidates it developed independently--EP37 for venous and arterial thrombosis and EP8000, which targets factors linked to angiogenesis, tumor growth, and metastasis.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies